Cholesteryl Ester Transfer Protein Inhibitors – Future Soon To Be REVEALed

Journal
Article on Cholesteryl Ester Transfer Protein Inhibitors – Future Soon To Be REVEALed

Add this Moment to your Passport

Learn from this moment and keep it forever.
FREE
Add To Passport

Overview

Reduction of the remaining residual cardiovascular risk is a clinical unmet need currently being addressed through a combination of further reduction of plasma concentrations of low-density lipoproteins (LDLs) and increasing plasma concentrations of high-density lipoproteins (HDLs). This brief review sets out the so-called HDL hypothesis and summarises the clinical results of the family of drugs, which function to raise plasma HDL concentration through inhibition of cholesteryl ester transfer proteins (CEPT).

Featuring

Christopher Huggins - Cardiovascular & Cell Sciences, St George’s, University of London, UK

Nicoletta Charolidi - Cardiovascular & Cell Sciences, St George’s, University of London, UK

Gillian W Cockerill - Cardiovascular & Cell Sciences, St George’s, University of London, UK

Loading Simple Education